Athersys, Inc. - ATHX STOCK NEWS

Welcome to our dedicated page for Athersys news (Ticker: ATHX), a resource for investors and traders seeking the latest updates and insights on Athersys stock.

Athersys, Inc. (symbol: ATHX) is a leading clinical-stage biopharmaceutical company dedicated to the discovery and development of innovative medications aimed at addressing significant and life-threatening diseases. The company leverages proprietary technologies to build a robust pipeline featuring highly differentiated, potential best-in-class therapeutics. These developments span multiple disease areas, including both stem cell therapy and pharmaceuticals.

Athersys is pioneering in the field of regenerative medicine with its flagship product, MultiStem®, an investigational stem cell therapy targeting critical conditions such as ischemic stroke, acute respiratory distress syndrome (ARDS), and other inflammatory and immune-mediated diseases. The company’s focus on extending and enhancing the quality of human life is evident through its diverse and strategic therapeutic programs.

Recent achievements include advancing clinical trials for MultiStem® and securing key partnerships that bolster the company’s research, development, and commercialization capabilities. Financially, Athersys remains committed to prudent management of resources, enabling sustained innovation and growth in its therapeutic pipeline.

With a strong emphasis on regulatory compliance, scientific rigor, and patient outcomes, Athersys continues to push the boundaries of medical science. The company’s mission is to deliver transformative therapies that address unmet medical needs, ultimately improving the lives of patients around the world.

For more in-depth and up-to-date information on Athersys, including the latest news and developments, please refer to the sources listed below:

--- (Insert latest news here) ---
--- (Insert latest news here) ---
--- (Insert latest news here) ---
--- (Insert latest news here) ---
--- (Insert latest news here) ---

11/16/2023 08:30 AM

News

Athersys Reports Third Quarter 2023 Financial Results and Business Highlights

Rhea-AI Summary

Athersys, Inc. (OTC: ATHX) Announces Financial Results and Business Update, Including Interim Analysis of Phase 3 MASTERS-2 Clinical Trial for MultiStem Cell Therapy. The company also secured funding through warrant exercise and a Memorandum of Understanding with Healios for global rights to develop and commercialize MultiStem for the treatment of Acute Respiratory Distress Syndrome (ARDS). Athersys appointed Ms. Jane Wasman as Chair of the Board of Directors. Financially, the third quarter of 2023 showed a decrease in revenue, research and development expenses, and general and administrative expenses compared to the same period in 2022, resulting in a net loss of $(3.8) million. Cash and cash equivalents were $1.0 million as of September 30, 2023, compared with $9.0 million as of December 31, 2022.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-11.79%

Tags

10/16/2023 04:52 PM

News

Athersys Extends Near Term Liquidity with Proceeds from Warrant Inducement and Global ARDS License with Healios to Explore Strategic Alternatives

Rhea-AI Summary

Athersys announces warrant exercise inducement offer to raise $3.9 million and receives $1.5 million payment from HEALIOS K.K.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-- %

Tags

10/10/2023 08:30 AM

News

Athersys Reports Interim Analysis Results of MASTERS-2 Clinical Study with MultiStem in Ischemic Stroke, Signs Memorandum of Understanding (MOU) for Global ARDS License with Healios

Rhea-AI Summary

Athersys announces inconclusive results from Phase 3 trial for stroke treatment and enters into MOU with Healios for respiratory distress syndrome treatment.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-60%

Tags

10/03/2023 04:30 PM

News

Athersys Licenses its Animal Health Assets to Ardent Animal Health

Rhea-AI Summary

Athersys signs licensing agreement with Ardent Animal Health for non-human mammal applications of MAPC technology in the US. Athersys will receive initial fee, milestone payments, and royalties on commercial sales. Ardent also granted rights of first refusal for Athersys' cryogenic storage system. Positive partnership for Athersys in expanding its regenerative medicine applications in animal health.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-- %

Tags

10/02/2023 05:04 PM

News

Athersys Director Jane Wasman Appointed Board Chair

Rhea-AI Summary

Athersys, Inc. announces changes to its Board of Directors. Jane Wasman appointed as Board Chair. Her expertise in strategic, operational, and corporate governance matters will be valuable. She is also chair of the board of directors of Sellas Life Sciences and a member of the board of directors of Rigel Pharmaceuticals. Positive for shareholder value.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-0.97%

Tags

09/06/2023 02:45 PM

News

Grant Awarded to Newcastle University to Research Athersys’ MultiStem® in Machine Perfusion Prior to Kidney Transplantation

Rhea-AI Summary

Athersys announces grant funding for study on potential use of MultiStem cellular therapy during machine perfusion prior to kidney transplantation

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-8.33%

Tags

08/17/2023 09:30 PM

News

Athersys, Inc. Announces Pricing of $3.5 Million Public Offering

Rhea-AI Summary

Athersys, Inc. announces the pricing of its public offering of common stock and warrants. The offering is expected to raise approximately $3.5 million for general corporate purposes.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-20.51%

Tags

08/16/2023 05:01 PM

News

Athersys Reports Second Quarter 2023 Financial Results and Business Highlights

Rhea-AI Summary

Athersys, Inc. (Nasdaq: ATHX) announced financial results for Q2 2023, with $48.8K in revenue compared to $2.3M in Q2 2022. Research and development expenses decreased to $10.6M from $20.8M, and general and administrative expenses decreased to $2.3M from $5.2M. Net loss for Q2 2023 was $(12.9)M, compared to $(23.6)M in Q2 2022. Cash and cash equivalents were $1.8M as of June 30, 2023.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-7.14%

Tags

08/11/2023 08:00 AM

News

Athersys Appoints Neema Mayhugh, PhD to its Board of Directors

Rhea-AI Summary

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-6.38%

Tags

07/31/2023 01:38 PM

News

Athersys to Host Business Update Conference Call on August 9th

Rhea-AI Summary

Athersys, Inc. (NASDAQ: ATHX) will host a business update conference call on August 9, 2023, at 4:30 p.m. Eastern Time. The call will provide an overview of the company's recent clinical and operational progress, including the timing to conduct an interim analysis with MASTERS-2, a Phase 3 pivotal trial of MultiStem treatment in ischemic stroke.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

4.48%

Tags

FAQ

What is the market cap of Athersys (ATHX)?

The market cap of Athersys (ATHX) is approximately 833.2K.

What is Athersys, Inc.?

Athersys, Inc. (symbol: ATHX) is a clinical-stage biopharmaceutical company focused on developing innovative therapies for significant and life-threatening diseases.

What is MultiStem®?

MultiStem® is Athersys's investigational stem cell therapy aimed at treating critical conditions like ischemic stroke and acute respiratory distress syndrome (ARDS).

What types of therapies is Athersys developing?

Athersys is developing both stem cell therapies and pharmaceuticals across multiple disease areas.

What are some recent achievements of Athersys?

Recent achievements include advancing clinical trials for MultiStem® and securing key research and commercialization partnerships.

What is the financial condition of Athersys?

Athersys is committed to prudent financial management, supporting continuous innovation and growth in its therapeutic pipeline.

How does Athersys aim to improve human life?

Athersys focuses on developing medicines designed to extend and enhance the quality of human life through innovative therapeutics.

Where can I find updates on Athersys?

For the latest updates, refer to the news section on the Athersys website or financial news platforms covering the company.

What is the significance of Athersys's therapeutic programs?

Athersys's programs address unmet medical needs and represent pioneering advancements in regenerative medicine and other therapeutic areas.

Who can benefit from Athersys's therapies?

Patients suffering from significant and life-threatening conditions such as ischemic stroke, ARDS, and various inflammatory diseases may benefit from Athersys's therapies.